Sangamo Therapeutics Announces Third Quarter 2020 Conference Call and Webcast
Sangamo Therapeutics (Nasdaq: SGMO) has announced the release date for its third quarter 2020 financial results, set for November 4, 2020, after market close. A conference call will follow at 5:00 p.m. ET, where financial results and business updates will be discussed. Interested participants can join via telephone or webcast, with specific dial-in numbers provided for domestic and international callers. A replay of the conference call will be available for one week thereafter.
- Scheduled release of Q3 financial results could provide clarity on company performance.
- The upcoming conference call may attract investor interest and enhance transparency.
- None.
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2020 financial results after the market closes on Wednesday, November 4, 2020. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide business updates.
The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The conference ID number for the call is 2575067. Participants may access the live webcast via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. A conference call replay will be available for one week following the conference call. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 2575067.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, ex vivo gene-edited cell therapy, in vivo genome editing, and genome regulation. For more information about Sangamo, visit www.sangamo.com.
